Johnson and Johnson (JNJ) Börsenkurse

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern...

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology PR...

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* 2024 Fourth-Quarter Earnings per share (EPS) of $1.41...

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PR Newswire TITUSVILLE, N.J., Jan. 21, 2025 Following U.S. FDA...

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer PR...

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of...